Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy

Histone deacetylase (HDAC) inhibitors have emerged as a new class of antitumor agent for various types of tumors. MPT0B291, a novel selective inhibitor of HDAC6, demonstrated significant antiproliferative activity in various human cancer cell types. However, MPT0B291 has very low water solubility, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Putri, Athika Darumas, Chen, Pai-Shan, Su, Yu-Lin, Lin, Jia-Pei, Liou, Jing-Ping, Hsieh, Chien-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541575/
https://www.ncbi.nlm.nih.gov/pubmed/34684020
http://dx.doi.org/10.3390/pharmaceutics13101728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541575/
https://www.ncbi.nlm.nih.gov/pubmed/34684020
http://dx.doi.org/10.3390/pharmaceutics13101728

Ejemplares similares